Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a premarket rating downgrade from J.P. Morgan Securities.
The investment firm lowered its rating on Valeant Pharmaceuticals to "underweight," which is pretty much the equivalent of a "sell," from "neutral," which is where its opinion of Valeant had sat for more than a year. It there is a bright side here, J.P. Morgan did increase Valeant's price target by 20% to $12 from $10 (albeit the stock had climbed to north of $22 at yesterdays close).
Source: Fool.com
Bausch Health Companies Inc. Stock
Currently there is a rather positive sentiment for Bausch Health Companies Inc. with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 7.26 € the target price of 16 € shows a potential of 120.39% for Bausch Health Companies Inc. which would more than double the current price.